Abstract
Glioma is the most frequent primary brain tumor. Recently, the upregulation of microRNA (miR)-23a was found to be associated with glioma, but the molecular mechanism by which miR-23a promotes glioma growth remains to be unveiled. In the present study, we found that miR-23a was significantly upregulated in glioma tissues compared to their matched adjacent tissues. miR-23a was also highly expressed in glioma cell lines SHG44, U251, and U87 cells. Moreover, we identified homeobox D10 (HOXD10) as a novel target for miR-23a. The expression of HOXD10 was significantly reduced in glioma tissues and cell lines, and miR-23a negatively regulates the protein expression of HOXD10 in U251 and U87 cells. We further showed that miRNA-23a promoted U251 and U87 cell invasion, at least partially, by directly targeting HOXD10 and further modulating MMP-14. These findings suggest that miR-23a may serve as a promising therapeutic target for glioma.
Highlights
We found that miR-23a was significantly upregulated in glioma tissues compared to their matched adjacent tissues. miR-23a was highly expressed in glioma cell lines SHG44, U251, and U87 cells
We further examined miR-23a expression in three glioma cell lines: SHG44, U251, and U87
The present study showed for the first time a novel molecular mechanism of miR-23a and homeobox D10 (HOXD10) in glioma cell invasion
Summary
The expression of HOXD10 was significantly reduced in glioma tissues and cell lines, and miR-23a negatively regulates the protein expression of HOXD10 in U251 and U87 cells. We further showed that miRNA-23a promoted U251 and U87 cell invasion, at least partially, by directly targeting HOXD10 and further modulating MMP-14. These findings suggest that miR-23a may serve as a promising therapeutic target for glioma. Several studies showed that the protein expression of HOXD10 was negatively regulated by miR-10b, an oncogenic miRNA in several cancers including glioma[15,16]. Whether other miRNAs are involved in the regulation of HOXD10 in glioma cells remains to be investigated
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
